Comparison of Application Effects Between Long Peripheral Venous Catheters and Standard Short Peripheral Venous Catheters: A Multicenter Prospective Randomized Controlled Trial Study

Status: Recruiting
Location: See location...
Intervention Type: Device, Other
Study Type: Interventional
Study Phase: Not Applicable
SUMMARY

Short PIVC (intravenous indentation needle) accounts for more than 50% of clinical infusion tools, but long PIVC is rarely used and studied in China. This study aims to explore the application characteristics and application effects of long PIVC in China. It provides reference for the correct selection of infusion tools, and promotes the clinical application and promotion of new intravenous therapy tools. The study nurse will work with the responsible physician to assess the eligibility for enrollment and sign the informed consent. Were randomly assigned to the control group (to receive a new 24G/22G (0.7mm\*19mm/0.9mm\*25mm) short PIVC (closed needle protected venous catheter system) puncture) or the intervention group (to insert a new 3F (8cm) or 4F(10cm) long PIVC) for daily routine maintenance until catheter removal, General demographic data, laboratory-related data, catheter-related data, catheter-related complications (unplanned extubation, phlebitis, catheter blockage, catheter-related thrombosis, catheter-related bloodstream infection, exudation, etc.) and patient satisfaction were collected.

Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Healthy Volunteers: f
View:

• A male or female aged 18 years or older who is able and willing to give written informed consent;

• Identification of the patient's medical diagnosis based on the competent physician and the study nurse at any time during the hospital stay, and judgment that the duration of peripheral intravenous infusion therapy needs to exceed 4 days;

• Subjects with good compliance and can cooperate with catheter maintenance and observation.

Locations
Other Locations
China
Deng Qiuxia
RECRUITING
Shenzhen
Contact Information
Primary
Qiuxia Deng
83762312@qq.com
+86 0755-61222333
Backup
Xiaoning Liu
xiaoning.liu21@imperial.ac.uk
075561222333
Time Frame
Start Date: 2023-12-05
Estimated Completion Date: 2024-12-31
Participants
Target number of participants: 250
Treatments
Experimental: Intervention group
In the intervention group, a new long peripheral venous catheter was selected by the puncture operator according to the puncture location and venous conditions, and was placed using aseptic technology. After blood return, the catheter could be easily rinsed with 0.9% sodium chloride solution, which was considered to be placed in the correct position and could be used normally. Intravenous infusion therapy begins immediately after successful catheterization. Check the condition of the catheter at least 3 times a day, and rinse with 10 ml.9% sodium chloride solution before each intravenous treatment; After disconnection of any infusion, pulse flushing with 0.9% sodium chloride solution 10ml and positive pressure sealing tube flushing to seal the catheter. Collect patient information, including sociodemographic information, duration of intravenous therapy, and details about catheter failure.
Active_comparator: Control group
The control group will receive a new 24G or 22G short peripheral venous catheter with direct view aseptic technique puncture, see blood return and rinse easily with 0.9% sodium chloride solution. The catheter is considered to be in the correct position and can be used normally. Check the condition of the catheter at least 3 times a day, and rinse with 10 ml.9% sodium chloride solution before each intravenous treatment; After disconnection of any infusion, pulse flushing with 0.9% sodium chloride solution 10ml and positive pressure sealing tube flushing to seal the catheter. Collect patient information, including sociodemographic information, duration of intravenous therapy, and details about catheter failure.
Related Therapeutic Areas
Sponsors
Leads: Shenzhen Third People's Hospital

This content was sourced from clinicaltrials.gov